AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

Rini, Brian; Szczylik, Cezary; M. Tannir, Nizar; Koralewski, P.; Tomczak, Piotr; Deptała, Andrzej; Dirix, Luc; Fishman, Mayer; Ramlau, Rodryg; Ravaud, Alain; Rogowski, Wojciech; Kracht, Karolyn; Sun, Yu‐Nien; Bass, Michael; Puhlmann, Markus; Escudier, Bernard

doi:10.1002/cncr.27632

Public

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

Published in Cancer • Jun 12, 2012

Authors:

Brian Rini

Cezary Szczylik

Nizar M. Tannir

Abstract

BACKGROUND: This study evaluated the tolerability and antitumor activity of AMG 386, a peptibody (a peptide Fc fusion) that neutralizes the interaction of angiopoietin-1 and angiopoietin-2 with Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like domains 2), plus sorafenib in patients with cl...

Subject

Medicine

Sorafenib

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!